Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 301 results
Flat illustration of a prostate gland and MRI scan

Oct 23, 2026

Five AI tools to spot prostate cancer backed for NHS use

The NHS is set to temporarily adopt five AI tools aimed at improving the detection of prostate cancer through MRI scans, as recommended by NICE, while further evidence is gathered regarding their effectiveness.NICE has approved the use of five AI technologies—AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate Intelligence, and QP-Prostate—over a two-year period funded by the NHS. This decision comes with the caveat that additional research is necessary for two other AI tools,
Press release cover image

Oct 22, 2026

FDA grants 510(k) clearance for BoneEnhance, the first machine learning layer on RIVANNA's Accuro XV platform

Anatomy segmentation and three-dimensional skeletal visualization arrive with this clearance; an injury detection module for clinical decision support is in development on the platform roadmapCHARLOTTESVILLE, Va., Oct. 22, 2026 /PRNewswire/ -- RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for BoneEnhance®, a machine learning software module for the Accuro® XV diagnostic ultrasou
Press release cover image

Oct 22, 2026

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with discographyAuthors conclude Nociscan “may, in time, replace provocative lumbar discography” in appropriately selected patientsBolsters the case for physician adoption and payor support for Nociscan BROOMFIELD,
Press release cover image

Oct 21, 2026

Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York

Median Technologies and its U.S. subsidiary eyonis Inc. will present eyonis® LCS at this landmark meeting of the international lung cancer screening communityI-ELCAP has played a pioneering role in advancing the scientific evidence and international adoption of low-dose CT lung cancer screeningThe conference will bring together many of the world’s leading experts in lung cancer screening, including I-ELCAP pioneersFollowing FDA clearance and CE marking, Median Technologies and eyonis Inc. are ad
Press release cover image

Oct 20, 2026

Sophont Launches Holon-S1 to Reveal Tumor Biology from Routine Pathology Slides

SACRAMENTO, Calif., Oct. 20, 2026 /PRNewswire/ -- Sophont, a frontier medical AI startup, announces Holon-S1, a pan-cancer AI model that predicts spatial gene and biological pathway activity from routine hematoxylin and eosin (H&E) pathology slides. By using widely available pathology slides, Holon-S1 aims to broaden access to insights that typically require costly and time-consuming molecular testing, supporting biomarker discovery and personalized treatment research.Continue Reading
A close-up of a tumor sample in a petri dish on a lab bench

Oct 20, 2026

‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses

Researchers at Elephas Biosciences are pioneering a novel approach to predict immunotherapy responses by creating a tumor "avatar" from patient biopsies.In collaboration with various academic institutions, Elephas has utilized 124 tumor samples to develop an algorithmic model that assesses how these samples respond to different immunotherapies, including anti-PD-L1 and anti-CTLA-4 treatments. This model measures responses through cytokines, which indicate whether the immune system is mounting an
Press release cover image

Oct 20, 2026

Azra AI Acquires Blackford Analysis to Close the Most Dangerous Gap in Healthcare: What Happens After the Scan

One platform now carries every imaging finding from the first scan to completed care, ending the era of AI flags that go nowhereNASHVILLE, Tenn., Oct. 20, 2026 /PRNewswire/ -- Every day, scans reveal signs of cancer, heart disease, and other serious illnesses that never turn into care. Azra AI, the industry-leading end-to-end enterprise platform that identifies patients who need care in real time and manages their journey from early suspicion through survivorship, today announced it has complete
Press release cover image

Oct 20, 2026

Philips highlights Integrated Diagnostics’ role in the future of cardiovascular informatics following MediReport acquisition

October 20, 2026 Advanced reporting and workflow capabilities developed by MediReport are expected to complement Philips’ cardiovascular informatics portfolio and support its evolution toward a more connected, AI-enabled and cloud-ready cardiovascular experience.  Amsterdam, the Netherlands – October 20, 2026 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to comp
MRI scanner in a dimly lit hospital imaging room with a technician

Oct 20, 2026

Subtle Medical Adds Distribution Partners in the UK and Italy to Support European Growth

Subtle Medical is expanding its European presence through new distribution agreements with AMG Medtech in the UK and Medical Horizons in Italy, aimed at addressing the rising demand for MRI and PET imaging solutions.The partnerships will facilitate the distribution of SubtleHD™(MR) and SubtleHD™(PET), AI-driven technologies designed to enhance the speed and quality of imaging exams. With over 1,500 scanners already utilizing Subtle Medical's software globally, the company is responding to signif
Press release cover image

Oct 20, 2026

Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC

Data featured as a Top Rated Oral Presentation at the 39th Annual Congress of the European Association of Nuclear MedicineFirst-in-human imaging performed in 10 patients with non-small cell lung cancer showed no tracer-related serious adverse events, high lesion contrast and tumor uptake that rose with c-MET expression, demonstrating high theranostic potentialGlobal regulatory clearances support advancing [225Ac]Ac-FL-261 into Phase 1 clinical trialsLONDON, Oct. 19, 2026 /PRNewswire/ -- Full-Lif
Press release cover image

Oct 19, 2026

EchoNous unveils Torso NXT, the next evolution of the Kosmos ultrasound platform

Top-tier image quality and AI clinicians trust, in a probe designed for POCUS users by POCUS usersREDMOND, Wash., Oct. 19, 2026 /PRNewswire/ -- EchoNous today introduced Torso NXT, the next generation of its flagship Torso probe for the Kosmos ultrasound platform. Designed to address the evolving demands of modern clinical imaging, Torso NXT is the first of many planned product introductions expanding the capabilities of Kosmos. The device delivers category-leading image quality, usability, and
Press release cover image

Oct 19, 2026

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

LOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, establishing the foundation for a multimodal diagnostic platform that combines blood-based biomarkers, imaging biomarkers, and artificial intelligence. The first product, a radiomics-based test for lung nodule risk assessment developed with Vanderbilt University and Vanderbilt Health, i